Redhill Biopharma (Redhill Biopharma) EV-to-Revenue

: 0.25 (As of Today)

View and export this data going back to 2013. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Redhill Biopharma's enterprise value is $9.01 Mil. Redhill Biopharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $35.75 Mil. Therefore, Redhill Biopharma's EV-to-Revenue for today is 0.25.

The historical rank and industry rank for Redhill Biopharma's EV-to-Revenue or its related term are showing as below:

RDHL' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.12 Med: 17.42 Max: 136733.4
Current: 0.25

During the past 13 years, the highest EV-to-Revenue of Redhill Biopharma was 136733.40. The lowest was -0.12. And the median was 17.42.

RDHL's EV-to-Revenue is ranked better than
97.17% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.33 vs RDHL: 0.25

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Redhill Biopharma's stock price is $0.452. Redhill Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $19.88. Therefore, Redhill Biopharma's PS Ratio for today is 0.02.

Redhill Biopharma EV-to-Revenue Historical Data

The historical data trend for Redhill Biopharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

27.03

5.71

2.16

1.87

3.73

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
EV-to-Revenue																1.94	1.87	0.01	-	-

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's EV-to-Revenue falls into.

Redhill Biopharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Redhill Biopharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	9.014	/	35.745
	=	0.25

Redhill Biopharma's current Enterprise Value is $9.01 Mil.
Redhill Biopharma's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.75 Mil.

Redhill Biopharma (NAS:RDHL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Redhill Biopharma's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.452	/	19.883
	=	0.02

Redhill Biopharma's share price for today is $0.452.
Redhill Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.88.

Redhill Biopharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.